Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in ty…

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials.

IsoEnergy to Acquire Toro Energy, Strengthening a Top-Tier Uranium Portfolio in a Rising Market

PERTH, Australia - Oct. 13, 2025 - IsoEnergy Ltd. ("IsoEnergy") (NYSE American: ISOU) (TSX: ISO) and Toro Energy Ltd. ("Toro") (ASX: TOE) are pleased to announce that they have entered into a scheme ...
BMJ Open

Prevalence and risk of adverse intrapartum-related outcomes in Uganda: a cross-sectional study with nested case–control

Introduction Intrapartum-related complications are a leading cause of adverse perinatal outcomes, including stillbirths, ...
AHA/ASA Journals

Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention: A Scientific Statement From ...

Coronary artery calcium (CAC) is a marker of subclinical atherosclerosis that confers increased risk of atherosclerotic cardiovascular disease. Measured by noncontrast cardiac computed tomography, CAC ...
The Lancet

Predicting stroke risk in women: are inflammation and atherosclerosis enough?

Stroke risk evolves across the lifespan, with distinct sex-specific differences that remain underappreciated in both research ...